Prescription Required
Formulation: Injection
(Brand Option)
Select the prescribed dosage
Select the quantity to see the price.
Prescription Required
Formulation: Injection
Select the quantity to see the price.
* This price includes a dispensing fee, medical review fee, and packing fee.
Shipped and delivered directly to your doorstep
Reclast contains the active ingredient zoledronic acid. It is a prescription medication used to strengthen bones, slow bone loss, and reduce the risk of fractures.
Reclast is given through a vein as an intravenous infusion by a healthcare professional. It is not taken every day. Depending on why you are receiving it, treatment may be given once a year or as a single dose.
Osteoporosis is a condition in which bones become thinner, weaker, and more likely to break. It often develops gradually and may not cause symptoms until a fracture occurs.
Reclast may be prescribed to treat osteoporosis in postmenopausal women and in men. It can help increase bone density and reduce the risk of fractures, including fractures of the hip and spine.
A hip fracture can affect mobility and independence, while spinal fractures may cause back pain, loss of height, or a curved posture. By slowing bone loss, Reclast helps make these fractures less likely.
Reclast may also be used to help prevent osteoporosis in certain postmenopausal women who are at increased risk of bone loss.
Reclast may be prescribed after a low-trauma hip fracture, such as a fracture caused by a fall from standing height.
People who have had one osteoporosis-related fracture are at greater risk of another. Reclast may help reduce the chance of future fractures and support long-term bone strength.
Long-term treatment with corticosteroid medications, such as prednisone, can cause bones to lose density more quickly. This is called glucocorticoid-induced osteoporosis.
Corticosteroids can reduce the body’s ability to build new bone, decrease calcium absorption, and increase bone breakdown. The risk is generally greater with higher doses and longer treatment.
Reclast may be used to prevent or treat bone loss in people who are expected to take corticosteroids for an extended period and are at increased risk of fractures.
Paget’s disease causes the normal process of bone breakdown and rebuilding to become unusually fast and disorganized.
The affected bone may become enlarged, weak, misshapen, or painful. Paget’s disease may affect the pelvis, spine, skull, legs, or other bones.
Possible complications include:
Reclast slows the abnormal bone-remodelling process. This can help reduce bone pain, improve bone structure, and lower the activity of the disease.
Bones are living tissues that are constantly renewed. Cells called osteoclasts break down old or damaged bone, while cells called osteoblasts build new bone.
In osteoporosis, bone is removed faster than it is replaced. This causes bones to gradually lose strength.
Reclast belongs to a group of medications called bisphosphonates. It attaches to bone and reduces the activity of osteoclasts. As bone breakdown slows, the body has more time to maintain or rebuild bone tissue.
Reclast does not create new bone immediately. Its main effect is to reduce excessive bone loss and improve bone strength over time.
You will not usually feel Reclast working. Your healthcare provider may monitor your response through bone-density scans, blood tests, fracture history, and other assessments.
Bone density may improve gradually over months or years. Even if you do not feel different, treatment may still be reducing your fracture risk.
Reclast is given through a vein by a healthcare professional. The infusion usually lasts at least 15 minutes.
For osteoporosis treatment, it is commonly given once a year. For osteoporosis prevention in certain postmenopausal women, it may be given once every two years. Paget’s disease is generally treated with a single infusion, although retreatment may be considered if the disease becomes active again.
Your exact schedule will depend on your condition, kidney function, treatment response, and risk of fractures.
Your healthcare provider may recommend calcium and vitamin D before and after treatment. These nutrients are important because Reclast can lower blood calcium, especially in people who already have low levels.
Your overall bone-health plan may also include:
Reclast is not suitable for everyone. Your healthcare provider will check your kidney function and blood calcium before treatment.
Tell your healthcare provider if you have kidney disease, low calcium levels, dehydration, dental problems, or difficulty absorbing nutrients. Also tell them about all medications and supplements you take.
Drink enough fluids before receiving Reclast unless your healthcare provider has told you to limit fluids. Dehydration may increase the risk of kidney problems.
Some people develop temporary flu-like symptoms after an infusion, including fever, chills, headache, tiredness, or muscle and joint aches. These symptoms are most common after the first dose and often improve within a few days.
Rare but serious risks may include kidney injury, very low calcium levels, unusual thigh-bone fractures, and damage to the jawbone. Your healthcare provider will consider these risks before recommending treatment.
Contact your healthcare provider promptly if you develop severe muscle cramps, tingling around your mouth, reduced urination, severe jaw pain, a nonhealing mouth sore, or new pain in your thigh or groin.
Attend all follow-up appointments and laboratory tests so your healthcare provider can confirm that Reclast remains safe and appropriate for you.
Reclast contains zoledronic acid and is given directly into a vein by a healthcare professional. The infusion must last at least 15 minutes.
Reclast is usually administered at a clinic, hospital, infusion centre, or healthcare provider’s office. It should not be prepared or injected by the patient at home.
You may usually eat normally on the day of your treatment. Drink at least two glasses of fluid within a few hours before your infusion unless your healthcare provider has told you to limit fluids because of a medical condition.
Staying well hydrated may help reduce the risk of kidney problems. Your healthcare provider may also order blood tests before the infusion to check your kidney function and calcium levels.
Tell your healthcare provider if you have recently experienced vomiting, diarrhea, fever, heavy sweating, or another condition that may have caused dehydration.
For postmenopausal women and men with osteoporosis, the usual dose is 5 mg given through a vein once a year.
Reclast may help increase bone strength and reduce the risk of fractures. Your healthcare provider will periodically review whether you still need treatment.
Dosage for osteoporosis caused by corticosteroids
For the treatment or prevention of osteoporosis caused by long-term glucocorticoid use, such as prednisone treatment, the usual dose is 5 mg given once a year.
Your healthcare provider will consider your corticosteroid dose, expected length of treatment, bone density, and fracture risk before recommending Reclast.
For the prevention of osteoporosis in certain postmenopausal women, the usual dose is 5 mg given once every two years.
This schedule is different from the once-yearly dose used to treat established osteoporosis.
Dosage for Paget’s disease of bone
For Paget’s disease, Reclast is usually given as a single 5 mg infusion.
Many patients do not need another dose for a long time. However, retreatment may be considered if the disease becomes active again or does not respond adequately to the first infusion.
Your healthcare provider may recommend calcium and vitamin D supplements, especially if you do not receive enough through your diet.
These nutrients help maintain healthy calcium levels and support bone strength. Take supplements exactly as directed.
Zoledronic acid is also available under other product names and dosing schedules for cancer-related conditions, including high calcium levels caused by cancer and bone complications from multiple myeloma or cancer that has spread to the bones.
Those cancer-treatment regimens are not Reclast dosing schedules. They may use a different strength, formulation, and treatment frequency.
Do not receive Reclast if you are already being treated with another zoledronic acid product or another intravenous bisphosphonate unless your healthcare provider specifically directs you to do so.
Some people develop temporary flu-like symptoms after receiving Reclast, particularly after the first infusion. These may include fever, chills, headache, tiredness, or muscle and joint aches.
These symptoms commonly begin within the first few days and usually improve within several days. Ask your healthcare provider whether acetaminophen or another medication is appropriate for managing these symptoms.
Contact your healthcare provider promptly if you experience reduced urination, severe weakness, muscle cramps, tingling around your mouth, severe jaw pain, or new pain in your thigh or groin.
Reclast (Zoledronic Acid IV Solution) is available in the following forms and strength:
Reclast can affect kidney function and, in rare cases, may cause serious kidney injury. The risk may be higher if you already have kidney disease, are dehydrated, are an older adult, or take other medications that can affect the kidneys.
Reclast should not be used if your creatinine clearance is below 35 mL/min or if you have signs of sudden kidney failure. Before each infusion, your healthcare provider will order a blood test to check your kidney function.
Drink enough fluids before receiving Reclast unless your healthcare provider has instructed you to limit fluids. Tell them if you have recently had vomiting, diarrhea, fever, heavy sweating, or another condition that may have caused dehydration.
Contact your healthcare provider promptly if you urinate less than usual, develop swelling in your legs or feet, or experience unusual weakness or tiredness.
Reclast can lower the amount of calcium in your blood. Any existing low calcium level must be corrected before you receive the infusion.
Your healthcare provider may recommend calcium and vitamin D supplements to help maintain healthy calcium levels. Take these supplements exactly as directed.
Contact your healthcare provider immediately if you develop possible symptoms of low calcium, such as:
The risk may be higher if you have vitamin D deficiency, thyroid or parathyroid problems, or difficulty absorbing nutrients.
Some people receiving Reclast have developed severe bone, joint, or muscle pain. This may begin within one day of the infusion, but it can also appear months later.
The pain may improve after treatment is stopped, although symptoms can sometimes return if Reclast or another bisphosphonate is given again.
Contact your healthcare provider if you develop severe or persistent pain. This is different from the temporary flu-like aches that commonly occur during the first few days after an infusion.
A rare but serious condition called osteonecrosis of the jaw has occurred in people receiving bisphosphonates such as Reclast. This condition happens when part of the jawbone becomes damaged and does not heal normally.
The risk may be higher if you have cancer, poor dental health, gum disease, dentures that do not fit properly, or are receiving corticosteroids, chemotherapy, or certain other treatments. Tooth extraction and other invasive dental procedures may also increase the risk.
Having dental problems does not automatically mean that you cannot receive Reclast. However, your healthcare provider should examine your mouth before treatment and may recommend a dental assessment, particularly if you have risk factors.
Tell your dentist that you receive Reclast. Maintain good oral hygiene and attend regular dental appointments. When possible, complete major dental work before beginning treatment.
Contact your healthcare provider or dentist if you develop:
Reclast may harm an unborn baby and should not be used during pregnancy.
Tell your healthcare provider if you are pregnant, think you may be pregnant, or plan to become pregnant. Zoledronic acid can remain in the bones for a long time after treatment, so discuss pregnancy planning with your healthcare provider before receiving an infusion.
It is not known whether zoledronic acid passes into human breast milk. Because Reclast may cause serious effects in a nursing baby, breastfeeding is not recommended during treatment.
Speak with your healthcare provider about the safest feeding and treatment options for your situation.
Before receiving Reclast, tell your healthcare provider about all your medical conditions, medications, supplements, and planned dental procedures.
Attend all scheduled blood tests and follow-up appointments. Do not receive another product containing zoledronic acid or another intravenous bisphosphonate unless your healthcare provider specifically directs you to do so.
You should not receive Reclast if you have a low calcium level in your blood, severe kidney impairment with a creatinine clearance below 35 mL/min, sudden kidney injury, an allergy to zoledronic acid or any ingredient in Reclast, or a current pregnancy. Your healthcare provider will check your kidney function and calcium level before each infusion. Tell them if you have kidney disease, are dehydrated, take a diuretic or “water pill,” or use medications that may affect your kidneys. Dental problems do not automatically prevent you from receiving Reclast. However, tell your healthcare provider if you have gum disease, poorly fitting dentures, an unhealed mouth sore, or a planned tooth extraction or dental surgery. A mouth examination is recommended before treatment because Reclast can rarely cause a serious jawbone condition called osteonecrosis of the jaw.
Reclast can interact with certain medications and may increase the risk of kidney problems or low calcium levels. Before your infusion, tell your healthcare provider about every prescription medication, over-the-counter product, vitamin, and supplement you take. This is especially important if you use diuretics, also called water pills; aminoglycoside antibiotics; nonsteroidal anti-inflammatory drugs such as ibuprofen or naproxen; other medications that may affect the kidneys; or another product containing zoledronic acid. Do not receive Reclast if you are already receiving Zometa because both medications contain zoledronic acid. Your healthcare provider will review your medication list and determine whether you need treatment changes, additional blood tests, or closer monitoring.
Yes. Reclast is approved to increase bone mass in men with osteoporosis. It may also be used to treat or prevent osteoporosis caused by long-term corticosteroid treatment in men and women. Your healthcare provider will consider your bone density, fracture history, medical conditions, and overall fracture risk before recommending treatment. Reclast is not specifically approved for bone loss caused by androgen-deprivation therapy, although a specialist may consider osteoporosis treatment based on an individual patient’s needs.
Zoledronic acid has a terminal plasma half-life of approximately 146 hours, or about six days. However, this number does not fully describe how long Reclast remains active. Some of the medication is removed through the kidneys, while the rest attaches strongly to bone. The zoledronic acid stored in bone is released very slowly, which allows a single infusion to affect bone turnover for a year or longer. For this reason, it is not accurate to say that Reclast is completely eliminated within a few months. Its effects on bone can continue long after the medication is no longer present at meaningful levels in the bloodstream. Your healthcare provider will periodically review whether and when another infusion is appropriate.
| Generic name: | Zoledronic Acid IV Solution |
|---|---|
| Formulation: | Injection |
| Strength(s): | 5mg/100mL |
| Quantities Available: | 1vial, 5vials |
Our online Canadian Pharmacy is known for high standards of quality, safety, and efficiency when it comes to medications.
Our pharmacy offers lower prices on prescription drugs compared to traditional pharmacies.
When ordering Reclast (zoledronic acid IV solution) from a Canadian pharmacy, you can typically purchase up to a 90-day supply at one time, which is common for prescription medications to ensure effective treatment management without frequent refills.
Here’s what you need to know:
Dosage and Quantity: Reclast is typically prescribed as a single intravenous infusion of 5 mg once yearly for conditions such as osteoporosis and Paget’s disease of bone. Therefore, for a 90-day supply of Reclast, you would order 1 infusion, aligning with the annual treatment regimen commonly recommended.
No, we do not sell zoledronic acid IV solution directly on our website. However, you can still enjoy competitive prices on Reclast, which contains zoledronic acid as an active ingredient. To purchase zoledronic acid IV solution from us, you will need a valid prescription from your healthcare provider. We require this prescription to dispense the medication safely and accurately. You can submit your prescription by mail, fax, or by uploading it through your online account for convenient processing.
Yes, we ship Reclast (zoledronic acid IV solution) to both the United States and Puerto Rico.
Watch how Online Pharmacies Canada is helping customers save money on their medications.
Online Pharmacies Canada has provided information from third parties intended to increase awareness and does not contain all the information about Reclast (Zoledronic Acid IV Solution). Talk to your doctor or other qualified medical practitioners for medical attention or advice, or if you have any concerns about Reclast (Zoledronic Acid IV Solution).
REVIEWS